The tweet was deleted by the author.
But we saved everything 🙂.
Biogen, in partnership with Eisai, has released new real-world data at the ADPD2026 conference examining long-term treatment persistence for people living with early Alzheimer disease in the U.S.
The data aims to shed light on how patients are maintaining therapy over extended periods, focusing on real-world applications rather than clinical trials alone. The findings are expected to inform future strategies for managing Alzheimer disease in its early stages.
View post on X Loading...
The latest Alzheimer disease data from Biogen and Eisai builds on a series of pivotal research disclosures from the company, including recent advances in spinal muscular atrophy highlighted at the 2026 MDA Conference. Furthermore, the firm's earlier presentation of Phase 1b results for an investigational SMA treatment underscores Biogen’s continued focus on neurological disorders and its commitment to expanding real-world evidence across therapeutic areas.